EN DE
STOCK COMPARISON

Merck & Company vs Thermo Fisher Scientific: Fair Value & Quality

Both stocks run through our valuation models. Here is how Merck & Company (MRK) and Thermo Fisher Scientific (TMO) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Merck & Company trades at $133 versus a fair value of $125 (-6%), while Thermo Fisher Scientific trades at $603 versus $308 (-49%).
Merck & Company
MRK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$133
Fair Value$125
Quality70/100
Thermo Fisher Scientific
TMO · USD · Health Care
-49%
upside to fair value
overvalued
Price$603
Fair Value$308
Quality63/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Merck & CompanyThermo Fisher Scientific
Valuation
38.5×P/E (TTM)29.5×
4.64×P/S (TTM)4.41×
5.80×P/B3.74×
11.4×EV/EBITDA20.0×
6.10×PEG1.74×
2.6%Dividend yield0.3%
$3.28Dividend per share$1.76
Profitability
14%Net margin15%
39%Operating margin18%
19%Return on equity14%
13%Return on assets5%
Growth
5%Revenue growth (YoY)6%
3.1%Avg. growth/yr (3Y)-0.3%
9.4%Avg. growth/yr (5Y)6.7%
Balance & size
0.89×Debt / equity0.67×
$305BMarket cap$199B
healthyGrowth qualityhealthy

Even match: 7 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Merck & Companyof which business quality 68 · market factors 85 Thermo Fisher Scientificof which business quality 60 · market factors 69
ProfitabilityMargins and returns on capital today
74
43
Quality GrowthAre margins and returns improving?
36
31
CashflowEarnings quality: real cash, not paper profit
65
62
Fin. StrengthBalance sheet, leverage, solvency risk
68
60
InvestmentDisciplined investing over empire-building
71
79
Low VolatilityCalm price path (market factor)
86
69
MomentumPrice trend over the last 3–12 months (market factor)
75
64
52W MomentumDistance to the 52-week high (market factor)
100
77
Net IssuanceBuybacks instead of dilution
91
97

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Merck & Company

DCF Models$117
Earnings-Based$62.77
Dividend Discount$60.35
Multiples$122
Asset-Based$14.27
Growth DCF$74.00
Economic Profit$83.85
Growth Earnings$138

19 of 26 models see the stock below the current price.

Thermo Fisher Scientific

DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341

24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Merck & Company
Bear $70.92Fair Value $125Bull $188
$133 = current price (white tick)
Thermo Fisher Scientific
Bear $171Fair Value $308Bull $385
$603 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-6% · above median

Thermo Fisher Scientific · Health Care

Quality score63 · Top 25%
Fair value upside-49% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Merck & Company trades at $133 versus a fair value of $125 (-6%), while Thermo Fisher Scientific trades at $603 versus $308 (-49%).

Merck & Company has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.